Found 4 matching trials
Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)
N/ASubjects will receive an oral dose of SER-109 in 4 capsules once daily for ...
Status
Approved For Marketing
Location
Multiple Locations
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
PHASE2The study will involve administering the study drug as a single dose of stu...
Location
North County Gastroenterology
ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection
PHASE3Cohort 1: Subjects who had a Clostridioides difficile infection (CDI) recur...
Location
(Investigator site)
ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
PHASE3Subjects will receive an oral dose of SER-109 in 4 capsules once daily for ...
Location
(Investigator site)